0001213900-22-024761.txt : 20220617 0001213900-22-024761.hdr.sgml : 20220617 20220509110838 ACCESSION NUMBER: 0001213900-22-024761 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biotech Acquisition Co CENTRAL INDEX KEY: 0001825413 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 545 WEST 25TH STREET STREET 2: 20TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: 8586920539 MAIL ADDRESS: STREET 1: 545 WEST 25TH STREET STREET 2: 20TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10001 CORRESP 1 filename1.htm

Biotech Acquisition Company

545 West 25th Street, 20th Floor

New York, NY 10001

 

May 9, 2022

 

VIA EDGAR

 

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549

 

Attention: Dillon Hagius
Laura Crotty
Ibolya Ignat
Kevin Vaughn

  

Re:

Biotech Acquisition Company
Amendment No. 4 to Registration Statement on Form S-4 (the “Registration Statement”)
Filed May 9, 2022

File No. 333-263577

  

Ladies and Gentlemen:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Biotech Acquisition Company hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4 p.m. ET on May 9, 2022, or as soon as practicable thereafter.

 

  Very truly yours,
   
  /s/ Albert F. Hummel
  Albert F. Hummel
  Chief Investment Officer and Director


 

cc:   Ellenoff Grossman & Schole LLP